JP2002505337A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002505337A5 JP2002505337A5 JP2000534567A JP2000534567A JP2002505337A5 JP 2002505337 A5 JP2002505337 A5 JP 2002505337A5 JP 2000534567 A JP2000534567 A JP 2000534567A JP 2000534567 A JP2000534567 A JP 2000534567A JP 2002505337 A5 JP2002505337 A5 JP 2002505337A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- compound
- composition
- substituted
- cooh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 20
- 229910052739 hydrogen Inorganic materials 0.000 description 13
- 239000001257 hydrogen Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 12
- 150000002431 hydrogen Chemical class 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 6
- 239000003443 antiviral agent Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 4
- -1 glutaryl Chemical group 0.000 description 4
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 4
- 239000002777 nucleoside Substances 0.000 description 4
- XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 description 4
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Chemical group C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 3
- GTBVPNLDJICROQ-UHFFFAOYSA-N 1,3-dihydrobenzimidazol-2-one;guanidine Chemical compound NC(N)=N.C1=CC=C2NC(O)=NC2=C1 GTBVPNLDJICROQ-UHFFFAOYSA-N 0.000 description 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 2
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 2
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 2
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 2
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 2
- DLGSOJOOYHWROO-WQLSENKSSA-N [(z)-(1-methyl-2-oxoindol-3-ylidene)amino]thiourea Chemical compound C1=CC=C2N(C)C(=O)\C(=N/NC(N)=S)C2=C1 DLGSOJOOYHWROO-WQLSENKSSA-N 0.000 description 2
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 2
- 229960004748 abacavir Drugs 0.000 description 2
- 229960004150 aciclovir Drugs 0.000 description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
- 229960001997 adefovir Drugs 0.000 description 2
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
- 229960003805 amantadine Drugs 0.000 description 2
- 229960001830 amprenavir Drugs 0.000 description 2
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 229960005319 delavirdine Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229960003804 efavirenz Drugs 0.000 description 2
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229960005102 foscarnet Drugs 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 229960002963 ganciclovir Drugs 0.000 description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
- 229930182480 glucuronide Natural products 0.000 description 2
- 150000008134 glucuronides Chemical class 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 229960001936 indinavir Drugs 0.000 description 2
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 229960003152 metisazone Drugs 0.000 description 2
- 229960000884 nelfinavir Drugs 0.000 description 2
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 2
- 229960000689 nevirapine Drugs 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 125000003835 nucleoside group Chemical class 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 229960000329 ribavirin Drugs 0.000 description 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 2
- 229960001225 rifampicin Drugs 0.000 description 2
- 229960000311 ritonavir Drugs 0.000 description 2
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 2
- 229960001852 saquinavir Drugs 0.000 description 2
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 2
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 description 1
- 125000000349 (Z)-3-carboxyprop-2-enoyl group Chemical group O=C([*])/C([H])=C([H])\C(O[H])=O 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000004031 fumaroyl group Chemical group C(\C=C\C(=O)*)(=O)* 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7644998P | 1998-03-02 | 1998-03-02 | |
| US60/076,449 | 1998-03-02 | ||
| PCT/US1999/004605 WO1999045025A1 (en) | 1998-03-02 | 1999-03-02 | Acylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002505337A JP2002505337A (ja) | 2002-02-19 |
| JP2002505337A5 true JP2002505337A5 (cg-RX-API-DMAC7.html) | 2006-04-20 |
Family
ID=22132095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000534567A Pending JP2002505337A (ja) | 1998-03-02 | 1999-03-02 | アシル化ベツリンおよびジヒドロベツリンの誘導体、その調製物、およびそれらの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6172110B1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1068219B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2002505337A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE348839T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU762404B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2322868C (cg-RX-API-DMAC7.html) |
| DE (1) | DE69934486T2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1068219T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2281960T3 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ506623A (cg-RX-API-DMAC7.html) |
| PT (1) | PT1068219E (cg-RX-API-DMAC7.html) |
| WO (1) | WO1999045025A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6232481B1 (en) * | 2000-01-11 | 2001-05-15 | Regents Of The University Of Minnesota | Method for manufacturing betulinic acid |
| US6656970B2 (en) * | 2000-05-11 | 2003-12-02 | Dabur Research Foundation | Method and compositions for solubilization of pentacyclic triterpenes |
| NZ538896A (en) * | 2002-09-26 | 2007-10-26 | Niigata University Of Pharmacy | Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
| US7365221B2 (en) * | 2002-09-26 | 2008-04-29 | Panacos Pharmaceuticals, Inc. | Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
| US7537765B2 (en) * | 2003-01-29 | 2009-05-26 | Panacos Pharmaceuticals, Inc. | Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein |
| US20040265320A1 (en) * | 2003-01-29 | 2004-12-30 | Karl Salzwedel | Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein |
| US7026305B2 (en) * | 2003-04-14 | 2006-04-11 | Meharry Medical College | Anti-HIV agents with dual sites of action |
| WO2005090380A1 (en) * | 2004-03-17 | 2005-09-29 | Panacos Pharmaceuticals, Inc. | Pharmaceuticals salts of 3-o-(3',3'-dimethylsuccinyl) betulinic acid |
| US7776863B2 (en) * | 2004-03-24 | 2010-08-17 | Bristol-Myers Squibb Company | Methods of treating HIV infection |
| US20050215544A1 (en) * | 2004-03-24 | 2005-09-29 | Pin-Fang Lin | Methods of treating HIV infection |
| WO2005112929A2 (en) * | 2004-05-20 | 2005-12-01 | Cornell Research Foundation, Inc. | Anti-hiv-1 activity of betulinol derivatives |
| US7282521B2 (en) * | 2004-05-24 | 2007-10-16 | University Of North Carolina At Chapel Hill | Anti-retroviral moronic acid derivatives |
| US8008280B2 (en) * | 2004-09-10 | 2011-08-30 | Biorings Llc | Betulinol derivatives as anti-HIV agents |
| TW200628161A (en) * | 2004-11-12 | 2006-08-16 | Panacos Pharmaceuticals Inc | Novel betulin derivatives, preparation thereof and use thereof |
| ES2383534T3 (es) * | 2005-04-12 | 2012-06-22 | Myrexis, Inc. | Polimorfos de di-N-metil-D-glucamina del ácido 3-O-(3',3'-dimetilsuccinil)betulínico |
| FI121468B (fi) * | 2006-06-07 | 2010-11-30 | Valtion Teknillinen | Betuliiniperäiset yhdisteet antimikrobisina aineina |
| US20080039428A1 (en) * | 2006-06-29 | 2008-02-14 | Panacos Pharmaceuticals, Inc. | Antiretroviral combination therapy |
| AR063546A1 (es) | 2006-11-03 | 2009-01-28 | Panacos Pharmaceuticals Inc | DERIVADOS DE TRITERPENO, METODOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA FABRICACION DE MEDICAMENTOS PARA EL TRATAMIENTO DE INFECCIoN POR EL VIRUS VIH. |
| US20110152229A1 (en) * | 2006-11-22 | 2011-06-23 | Duke University | Betulinic acid derivatives as anti-hiv agents |
| US8269026B2 (en) * | 2008-01-03 | 2012-09-18 | Vertex Pharmaceuticals Incorporated | Lupane derivatives useful for treating HIV |
| KR100941595B1 (ko) * | 2008-06-05 | 2010-02-11 | 주식회사 알앤엘바이오 | 바이러스 억제제로서 유용한 트리테르페노이드계 화합물 |
| US20100104669A1 (en) * | 2008-10-28 | 2010-04-29 | Scheffler Armin | Method for preparing an aqueous solution containing triterpenic acid, aqueous solution containing triterpenic acid, and use thereof |
| CN103038245B (zh) * | 2010-06-04 | 2015-03-25 | 百时美施贵宝公司 | 作为hiv成熟抑制剂的c-3经修饰的桦木酸衍生物 |
| EP2576586B1 (en) * | 2010-06-04 | 2015-08-12 | Bristol-Myers Squibb Company | C-28 amides of modified c-3 betulinic acid derivatives as hiv maturation inhibitors |
| RU2496785C1 (ru) * | 2012-09-24 | 2013-10-27 | Федеральное государственное бюджетное учреждение науки Институт технической химии Уральского отделения Российской академии наук (ИТХ УрО РАН) | Тритерпеноиды с фрагментом ен-нитрила в а-пентацикле |
| PL227790B1 (pl) | 2015-08-13 | 2018-01-31 | Slaski Univ Medyczny W Katowicach | Fosfoniany acetylenowych pochodnych betuliny o działaniu przeciwnowotworowym, sposób ich wytwarzania i zastosowanie. |
| PL237998B1 (pl) | 2018-05-28 | 2021-06-28 | Narodowy Inst Lekow | Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01143832A (ja) * | 1987-12-01 | 1989-06-06 | Toa Nenryo Kogyo Kk | 制癌剤 |
| FR2683531B1 (fr) * | 1991-11-13 | 1993-12-31 | Rhone Poulenc Rorer Sa | Nouveaux derives du lupane, leur preparation et les compositions pharmaceutiques qui les contiennent. |
| US5679828A (en) * | 1995-06-05 | 1997-10-21 | Biotech Research Labs, Inc. | Betulinic acid and dihydrobetulinic acid derivatives and uses therefor |
-
1999
- 1999-03-02 ES ES99909758T patent/ES2281960T3/es not_active Expired - Lifetime
- 1999-03-02 AT AT99909758T patent/ATE348839T1/de not_active IP Right Cessation
- 1999-03-02 US US09/260,078 patent/US6172110B1/en not_active Expired - Fee Related
- 1999-03-02 DE DE69934486T patent/DE69934486T2/de not_active Expired - Fee Related
- 1999-03-02 DK DK99909758T patent/DK1068219T3/da active
- 1999-03-02 NZ NZ506623A patent/NZ506623A/xx unknown
- 1999-03-02 PT PT99909758T patent/PT1068219E/pt unknown
- 1999-03-02 CA CA002322868A patent/CA2322868C/en not_active Expired - Fee Related
- 1999-03-02 WO PCT/US1999/004605 patent/WO1999045025A1/en not_active Ceased
- 1999-03-02 AU AU28894/99A patent/AU762404B2/en not_active Ceased
- 1999-03-02 EP EP99909758A patent/EP1068219B1/en not_active Expired - Lifetime
- 1999-03-02 JP JP2000534567A patent/JP2002505337A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002505337A5 (cg-RX-API-DMAC7.html) | ||
| CN1195526C (zh) | 含对映体纯β－D－二氧戊环核苷的药物产品 | |
| US6153594A (en) | 5'-O-acylated antiviral nucleosides | |
| JP5230052B2 (ja) | フラビウイルスおよびペスチウイルス治療のための方法および組成物 | |
| JP2851094B2 (ja) | ピリミジン誘導体 | |
| JP3474073B2 (ja) | ウリジンまたはシチジンのアシル誘導体を含有する医薬組成物 | |
| US6680303B2 (en) | 3′,5-difluoro-2′,3′-didehydropyrimidine nucleosides and methods of treatment therewith | |
| JP2002519355A5 (cg-RX-API-DMAC7.html) | ||
| US6548486B1 (en) | Fatty acid esters of nucleoside analogs | |
| TW201217392A (en) | Substituted nucleotide analogs | |
| JP2008255121A (ja) | 抗ｂ型肝炎ウイルス活性を有するヌクレオシド | |
| JP2818299B2 (ja) | ウイルス感染の治療におけるジデオキシヌクレオシドアナローグの使用 | |
| JP2007501800A5 (cg-RX-API-DMAC7.html) | ||
| ES2488821T3 (es) | Proceso de preparación de un compuesto antiviral | |
| WO1992016215A1 (en) | Use of 3'-azido-2',3'-dideoxyguanosine for the treatment of hepatitis b | |
| US20170232010A1 (en) | Drug with activity against the herpes virus family | |
| US20110190226A1 (en) | C4'-substituted-2-deoxyadenosine analogs and methods of treating hiv | |
| JP2005516066A5 (cg-RX-API-DMAC7.html) | ||
| AU672369C (en) | Chemical compounds | |
| HK1003437B (en) | Antiviral compounds | |
| IE930047A1 (en) | Chemical compounds |